Sat - Wed 8.30 - 16.00

+98 21 86085141

Number 21, Joibar Alley, Shad Street, Mollasadra Street , Tehran - Iran

Home  /  News  / 

RALEIGH, N.C., May 20, 2019

Merz Americas CEO Bob Rhatigan named “Top Aesthetics CEO” for the third year in a row

Key products XEOMIN®(incobotulinumtoxinA) and Ultherapy® recognized with best-in-class awards

RALEIGH, N.C., May 13, 2019

Merz Americas announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XEOMIN®(incobotulinumtoxinA), broadening its indication to be a first-line treatment of blepharospasm (involuntary blinking) in adult patients.

Frankfurt, Germany, May 29, 2019

First and only botulinum neurotoxin approved for this indication in Europe

Merz, a global leader in neurotoxin therapy, announced today the European approval of Xeomin®(incobotulinumtoxinA) for the symptomatic treatment of chronic sialorrhea (drooling) due to neurological disorders in adult patients.[1] Xeomin® is the first and only neurotoxin with this approved indication in the EU, which follows the US FDA approval in July 2018.[2]

Frankfurt, Germany, April 5, 2019
The new hyaluronic acid (HA) filler works beneath the skin to improve skin hydration, reduce redness and roughness and minimize the appearance of fine lines.

Contractubex® works deep inside the skin, and reduces scars thanks to its

pharmacologically active ingredients (extractum cepae, heparin & allantoin).

The Contractubex® lasting triple effect means:

  • Prevention of excessive scar tissue formation5
  • Reduction in redness, itching and the feeling of tension6,12
  • Lasting improvement of scar appearance5

For best possible results, treatment should be started as soon as the wound is closed or the stitches are removed. Contractubex® – for nearly invisible scars.

In recent years, awareness for the danger of skin cancer has been continuously on the rise – meanwhile even the biggest sun worshipper is aware that the skin can be permanently damaged. In Germany, for example, every year about 24,000 people contract skin cancer, a so-called malignant melanoma. The risk of developing skin cancer over a lifetime is about 1:200 in Germany and 1:50 in Australia.

Melanomas frequently develop from already existing birthmarks. Therefore, the risk of contracting skin cancer rises in relation to the number of birthmarks or pigment spots which a person has.


Fractured bones are amongst the most frequent consequences of accidents. Especially children injure themselves when playing or doing sport – and an inattentive moment quickly results in a fractured arm or a broken leg. The figures speak for themselves: By the time they’ve turned 16, every 2nd boy and every 3rd girl has already suffered a broken bone at one time.


Many women are affected by breast cancer, and in many cases it is fortunately able to be healed. For this however surgery is often necessary. An early treatment of the scar should be started so that no visible memories of this difficult time are left by the surgery.

Singapore, November 21, 2018

11 influential women representing 11 different countries in the Asia Pacific region join Merz Aesthetics to start a conversation about creating positive behaviors, attitudes and mindsets when it comes to self-confidence, beauty and ways of enhancing one’s appearance, including medical aesthetics treatments.


RALEIGH, N.C. , OCTOBER 26, 2016 

Radiesse Marks Key Milestone with Revealing Patient Survey Results

Merz Aesthetics, a division of Merz North America (U.S. affiliate of Merz Pharma Group) announced the 10-year anniversary of the launch of their flagship brand, RadiesseÒ. Radiesse is a volumizing filler used in more than 60 countries, and is unique in its ability to provide instant lift and stimulate the natural production of collagen with just one injection. More than 6 million syringes have been purchased by professionals worldwide over the past ten years.

Raleigh, NC, US, October 26, 2018

For the second year in a row, Merz has been recognized as the “Top Aesthetics Company” by Aesthetic Everything® and Bob Rhatigan has been named the “Top Aesthetics CEO.” As part of the annual Aesthetic and Cosmetic Medicine Awards, Merz executives and products were also recognized with 14 additional award wins – 16 total wins overall.

RADIESSE® has been used to treat patients in over 57 countries worldwide. Radiesse was FDA approved for subdermal implantation for the correction of moderate to severe wrinkles and folds in 2006, and since that time over 6 million syringes have been sold worldwide. Radiesse works to add volume and may instantly hide the signs of wrinkles and creases for a more refreshed look. Individual results may vary.

In clinical studies, RADIESSE patients were more satisfied with the results they received from treatments with RADIESSE versus leading fillers.2,4 In a head-to-head, 12-month study comparing RADIESSE to Restylane® Injectable Gel, 67% of patients preferred RADIESSE treatment.4

Replenishing lost volume and providing lift are two keys to diminishing the appearance of facial wrinkles and folds. There are two physical characteristics that dictate the ability of injectable fillers to provide volume and lift: viscosity and elasticity (G´).

RALEIGH, N.C., December 6, 2018

Fresh campaign breaks traditional medical aesthetics marketing approach to stomp out the stigma and tap into a new segment of women, The Reclaimers.


RALEIGH, N.C., October 25, 2018

Results presented at 2018 AAPM&R Annual Assembly show long-term improvement in adult patients with chronic sialorrhea (or excessive drooling)

In the past, Caesarean sections were primarily carried out for medical reasons. Nowadays, however, many mothers choose elective Caesareans.

A Caesarean section is a surgical procedure that leaves a scar. To allow the best possible recovery, the scar should be treated with Contractubex® as early as possible.

Many people suffer from acne during their youth. In most cases, this disappears over time and, with appropriate treatment, does not leave any traces behind. In some cases, e.g. with especially pronounced acne, disturbing scars can however remain. Many of those affected want to have the acne scars removed for the long term.

Radiesse® treatment restores a natural, youthful look that lasts.

  • Radiesse® is the only injectable dermal filler that immediately replenishes lost volume, gives the lift you need to produce an overall smoother, more youthful appearance, and stimulates the skin's natural collagen to grow. This process continues for several months, extending the positive initial effect.
  • Treatment with Radiesse® is quick. There is little to no down-time involved in a Radiesse® treatment. In fact, most patients return to their daily activities right after their visit.


Usually the treatment with Belotero® fillers is quick, typically taking about 30 minutes. You will most likely be able to continue your daily activities as soon as your appointment is over.

The skin on the face changes in different phases. Forehead wrinkles develop, for example, quite early, as well as the wrinkles around the eyes (crow's feet, laugh lines). These types of wrinkles are also called dynamic wrinkles or expression lines because they are caused by increased movement of the facial muscles.

For women in particular small hairs on the face, legs or groin can be a worry. Shaving, waxing or epilation only deal with the problem temporarily. And each method can cause redness, or even inflammation if hair decides to grow inwards.

Many people know the feeling – you no longer like a tattoo you got years ago and wish nothing more for it to disappear forever. Fortunately, there are good options for tattoo removal. Laser treatment is one of the most common methods.

It can take months—and sometimes years—for nasaltip edema to resolve after rhinoplasty, which can be challenging for patients and surgeons. Although various conventional modalities have been used to counteract edema, they are not successful for all skin types or in all situations. With the advent of the Ultherapy Ulthera System (Ulthera,Inc.,Mesa,Ariz.),thecapabilitynowexiststo safely and reliably manipulate the contour of the skin to permit the skin to conform optimally to the underlying cartilaginous framework. Thus, the cartilage and skincanworkintandemtocreateamoreidealnasal-tip configuration. 

Background: High intensity microfocused ultrasound Ulthera@ is expanding to be used for consistent significant lifting of upper and lower face tissue in a broad range of patients. Extensive research pipeline support expanded indications i.e. face, upper eyelid & neck lift, lower eyelid tightening & the improvement of dark circle, breast lift, and body tightening etc.

Objective: To investigate the efficacy and safety of Xeomin for treating troublesome sialorrhea.

Background: Uncontrolled sialorrhea results from various causes including Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS). Botulinum toxin A/B improves sialorrhea in PD and ALS, as shown here with Xeomin.


  • Allergies: Hyaluronic acid is found in every human body and is therefore very well tolerated.

Through a healthy lifestyle, you help the skin to preserve its beauty. As time goes on, it can still happen that the look in the mirror is no longer satisfactory. Here, aesthetic treatments can help! The Merz Aesthetics product range offers natural solutions for individual problem areas:

RALEIGH, N.C., July 3, 2018

First and only neurotoxin approved for this indication in the United States.

Merz North America announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XEOMIN®(incobotulinumtoxinA) for the treatment of chronic sialorrhea, or excessive drooling, in adult patients. XEOMIN is the first and only neurotoxin with this approved indication in the U.S.

RALEIGH, N.C., April 17, 2018

Merz announced today that Ultherapy®, Radiesse® and Cellfina® have been named the best “In-Office Treatments” by NewBeauty Magazine. In addition, Cellfina® was recognized as the “Best Non-Surgical Body Shaping Device” by THE European Aesthetic Guide.

Frankfurt am Main, April 9, 2018

Merz, a global leader in medical aesthetics, today announced the launch of Belotero® Lips, with products specifically designed for lip enhancement and treatment of perioral lines. The line includes two hyaluronic acid (HA) dermal filler products that complement each other to deliver safe, effective and natural-looking cosmetic results.

Frankfurt am Main, Germany, March 9, 2018

110 years ago, on March 9, 1908, Friedrich Merz founded the Chemische Fabrik Merz & Co. in Frankfurt am Main, Germany. Today, the traditional company in Frankfurt is still family-owned, but it has evolved from a mid-sized pharmaceutical company into a leading global provider in the fields of medical aesthetics and neurotoxins.

RALEIGH, N.C., March 9, 2018

Merz North America announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (sBLA) for Xeomin® (incobotulinumtoxinA) for the treatment of chronic sialorrhea (excessive drooling) due to Parkinson’s Disease or other neurologic disorders in adult patients. The sBLA is based on a Phase III study, which met both of its coprimary endpoints for subjects administered 100 U incobotulinumtoxinA by achieving statistically significant change in unstimulated salivary flow rate (uSFR), and in the subjects’ Global Impression of Change Scale (GICS). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date in Q4 2018, and if approved, has the potential to make Xeomin the first neurotoxin with this indication in the U.S.

The Michael J. Fox Foundation, one of the largest and most influential Parkinson’s organizations in the world, created an original article on the U.S. Food and Drug Administration’s (FDA) application acceptance of XEOMIN® for sialorrhea in adult Parkinson’s patients.

September 21, 2017 09:00 AM Eastern Daylight Time

Merz North America CEO Bob Rhatigan named the Top Aesthetics CEO Cellfina® and Ultherapy® Also Recognized as Top Procedures

RALEIGH, N.C.--(BUSINESS WIRE)--Merz North America, Inc. announced today that Merz has been recognized by Aesthetic Everything® as the Top Aesthetics Company and the winner of four other 2017 Diamond Crystal Awards, including the recognition of Cellfina® as the Top Minimally Invasive Procedure and Ultherapy® as a Top Non-Surgical Procedure in the Industry. In addition, Merz North America CEO Bob Rhatigan was named the Top Aesthetics CEO.

  • Aesthetic Industry Award Logo 2017
  • New Beauty Logo 2017

RALEIGH, N.C. – December 4, 2017

Merz announced today Ultherapy has been named the “Best Skin Tightening Device” by THE Aesthetic Guide, a leading aesthetic industry publication. Ultherapy® is the only FDA- cleared non-invasive procedure that lifts and tightens the neck, chin and brow, and improves lines and wrinkles on the chest.

RALEIGH, N.C., March 30, 2016 


Merz Aesthetics, a division of Merz North America (US affiliate of the global Merz Pharma Group) announced today that Ultherapy® has been named “Best Nonsurgical Skin Tightener” in the 2016 Beauty Choice Awards. This is the 3rd consecutive year Ultherapy® has been recognized by NewBeauty readers and editors in their Beauty Choice Awards. Ultherapy® is the first and only treatment FDA-cleared to non-invasively lift the eyebrow, neck, and chin, and to improve lines and wrinkles on the décolletage.

Frankfurt am Main, Germany, Sep 14, 2017

Merz today announced the commercial availability of the Cellfina® System in select European markets. The Cellfina® System is currently the only EU CE-Marked and U.S. FDA-cleared minimally-invasive procedure that treats the underlying structural cause of cellulite with results that last at least three years.  Cellfina® is intended for long-term reduction of cellulite by precise release of targeted structural tissue (fibrous septae).

Raleigh, N.C., USA, Jun 5, 2017

Merz Aesthetics, a division of Merz Pharma Group, announced that the Cellfina® System has been named a 2016 RealSelf Most Worth It award winner in the “Cellulite Treatment” category.

Frankfurt, Germany and Raleigh, N.C., USA, October 6, 2017

Ms. Brinkley Chooses Xeomin®/Bocouture® (incobotulinumtoxinA) and Ultherapy® to Help Her Look Her Best

Merz announced today its partnership with supermodel, actress and entrepreneur, Christie Brinkley to help empower women to live, feel and look their best at any age by sharing tips she’s learned from maintaining her youthful appearance during her 45-year span in the beauty and fashion industries. Through this initiative, Ms. Brinkley, a mom, actress and entrepreneur, shares why she chose to have the lines between her brows treated with Xeomin®/Bocouture® (incobotulinumtoxinA) and Ultherapy®, the non-surgical skin tightening and lifting treatment, on her neck and décolletage to remain looking timeless and natural at age 63.

Merz Neurosciences says two doses of its therapy Xeomin (incobotulinumtoxin A) effectively treat chronic drooling among patients with Parkinson’s disease and other illnesses.

Radiesse® – a success story that keeps unfolding.

The Belotero® range is manufactured using a highly innovative patented Dynamic Cross-Linking Technology (DCLT) that leads to a Cohesive Polydensified Matrix (CPM).

Merz Aesthetics, a division of Merz Pharma Group, announced in Frankfurt on 18th of May 2017 that Ultherapy® is celebrating the milestone achievement of conducting one million treatments globally. Since its global launch in 2008 and U.S. launch in 2009, the non-invasive ultrasound device has become a game-changer in physician offices worldwide for lifting and tightening skin with its cutting-edge technology. The revolutionary treatment is currently the first and only treatment FDA-cleared to non-invasively lift the eyebrow, neck, and chin, and to improve lines and wrinkles on the décolletage via microfocused ultrasound. Ultherapy® also conforms to the European level of quality and safety for medical devices.

Sialorrhea study (SIAXI) successfully completed.

Sialorrhea (drooling) can be a troublesome and disabling symptom resulting from various causes including Parkinson’s Disease (PD), cerebral palsy, amyotrophic lateral sclerosis (ALS) and various degenerative brain disorders. Merz completed the largest controlled study to date of incobotulinumtoxinA (Xeomin®) in the treatment of sialorrhea due to PD and other etiologies. Injection of doses of 75U and 100U of incobotulinumtoxinA (Xeomin) into the submandibular and parotid salivary glands are effective up to 16 weeks for treatment of troublesome chronic sialorrhea with more beneficial results for the 100 U treatments without meaningful added risks for adverse effects.